

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Bayer Pharmaceuticals Corporation	11/13/2007

RECEIVING PARTY DATA

Name:	Bayer HealthCare LLC
Street Address:	555 White Plains Road
City:	Tarrytown
State/Country:	NEW YORK
Postal Code:	10591

PROPERTY NUMBERS Total: 10

Property Type	Number
Application Number:	09776936
Application Number:	09640780
Application Number:	11768112
Application Number:	09472232
Application Number:	11768533
Application Number:	10060396
Application Number:	09458014
Application Number:	09776935
Application Number:	10086417
Application Number:	09778039

CORRESPONDENCE DATA

Fax Number: (703)243-6412

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 7032436333

Email: jacobs@mwzb.com

PATENT

500715396

REEL: 021893 FRAME: 0336

OP \$400.00 09776936

Correspondent Name: Millen, White, Zelano & Branigan, P.C.
Address Line 1: 2200 Clarendon Blvd.
Address Line 2: #1400
Address Line 4: Arlington, VIRGINIA 22201

ATTORNEY DOCKET NUMBER:

BAYER-0148X

NAME OF SUBMITTER:

Richard J. Traverso

Total Attachments: 110

source=ASSIGNMENT DOCUMENT-11-26-08#page1.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page2.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page3.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page4.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page5.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page6.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page7.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page8.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page9.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page10.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page11.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page12.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page13.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page14.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page15.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page16.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page17.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page18.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page19.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page20.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page21.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page22.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page23.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page24.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page25.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page26.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page27.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page28.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page29.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page30.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page31.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page32.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page33.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page34.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page35.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page36.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page37.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page38.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page39.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page40.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page41.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page42.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page43.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page44.tif

[illegible]

source=ASSIGNMENT DOCUMENT-11-26-08#page100.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page101.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page102.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page103.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page104.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page105.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page106.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page107.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page108.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page109.tif
source=ASSIGNMENT DOCUMENT-11-26-08#page110.tif

Asset Purchase Agreement

between

Bayer Pharmaceuticals Corporation
400 Morgan Lane, West Haven
Connecticut 06516
U.S.A.

and

Bayer HealthCare LLC
555 White Plains Road
Tarrytown, NY

ARTICLE 1	DEFINITIONS	1
ARTICLE 2	ASSIGNMENT	1
ARTICLE 3	PAYMENT	
ARTICLE 4	[REDACTED]	
ARTICLE 5	REPRESENTATIONS AND WARRANTIES	1
ARTICLE 6	[REDACTED]	
ARTICLE 7	TERM AND APPLICABLE LAW	
ARTICLE 8	MISCELLANEOUS	
ANNEX 1	BPC PATENTS	

ASSET PURCHASE AGREEMENT

This Asset Purchase Agreement is made as of August 13, 2007, to be effective as of August 1, 2007 (the "Effective Date") between Bayer Pharmaceuticals Corporation, a Delaware corporation ("BPC") and Bayer HealthCare LLC, a Delaware limited liability company ("BHC").

RECITALS

[REDACTED]

BPC is the owner of proprietary rights including patents, patent applications, know-how, trademarks, and copyrights related to its oncology portfolio. BPC is willing to assign certain of such rights and materials to BHC, and BHC is willing to accept such assignments, subject to the terms of and conditioned upon this Agreement.

For the above reasons, BPC and BHC agree as follows with the intent to be legally bound:

AGREEMENT

Article 1

Definitions

1.1 "Affiliate" shall mean any person or business entity which directly or indirectly controls, is controlled by, or is under common control with a Party to this Agreement. A business entity shall be deemed to "control" another business entity, if it owns directly or indirectly, fifty percent (50 %) or more of the outstanding voting security, capital stock, or other comparable equity or ownership interest of such business entity, or exercises equivalent influence over such entity. If the laws of the jurisdiction in which such entity operates prohibit ownership by a person or entity of fifty percent (50%) or more, "control" shall be deemed to exist at the maximum level of

ownership allowed by such jurisdiction, provided that such person or entity has the power to direct the management and policies of such entity.

1.2 "Agreement" shall mean this Asset Purchase Agreement.

1.3 "Assets" shall collectively mean the Patents and the Know-How.

1.4 [REDACTED]

1.5 [REDACTED]

1.6 "Effective Date" shall have the meaning set forth in the introductory paragraph hereto.

1.7 "Know-How" means any non-public, proprietary technology, information, data, protocols, formulas, chemistry, synthetic intermediates, methods of use, processes, techniques, discoveries, ideas, improvements, inventions and trade secrets, which are not disclosed in any Patents and which are directly related to, or used in connection with the subject matter of the Patents.

1.8 "Parties" shall mean BHC and BPC, and "Party" means either BHC or BPC.

1.9 "Patents" shall mean the patents and patent applications as listed in Annex 1 attached to this Agreement and, in each case, all patents granted thereon or claiming priority thereto or claiming common priority therewith, including all substitutions, divisions, continuations, continuations-in-part, reissues, reexaminations or extensions of any of such patent applications or patents, and respective supplementary protection certificates, and any foreign equivalents thereof.

1.10 [REDACTED]

[REDACTED]

1.11 [REDACTED]

1.12 [REDACTED]

Article 2

Assignments and License

2.1 BPC hereby sells, assigns and transfers its entire right, title and interest in and to the Assets to BHC, and BHC hereby accepts said Assets.

2.2 As of the Effective Date, BHC assumes all responsibility for all prosecution, maintenance, defense, enforcement, and extension of the Assets worldwide. [REDACTED]

2.3 [REDACTED]

2.4 [REDACTED]

Article 3

Payment

3.1 In consideration of the assignment and transfer of the Assets according to Article 2 from BPC to BHC, BHC shall pay to BPC [REDACTED]

[REDACTED] BPC acknowledges that this payment is full and complete compensation for the Assets assigned and transferred to BHC under this Agreement, and that neither BHC nor its Affiliates shall be required to pay any other consideration to BPC with respect to the assignment and transfer of the Assets hereunder. [REDACTED]

3.2 [REDACTED]


Article 4

Representations, Warranties and Covenants

4.1 **Representations, Warranties and covenants of BHC.** BHC represents, warrants and covenants that the execution and performance of this Agreement: is within the corporate power of BHC, has been duly authorized by all necessary corporate action, and does not conflict with or violate any requirement of applicable federal, state, or local laws or regulations.


4.2 **Representations, Warranties and covenants of BPC.** BPC represents, warrants and covenants that the execution and performance of this Agreement: is within the corporate power of BPC, has been duly authorized by all necessary corporate action, and does not conflict with or violate any requirement of applicable federal, state, or local laws or regulations.

4.3



Article 5

5.1



[REDACTED]

5.2

[REDACTED]

5.3

[REDACTED]

5.4

[REDACTED]

5.5

[REDACTED]

[REDACTED]

5.6 [REDACTED]

Article 6
Term and Applicable Law

6.1 This Agreement shall become effective on the Effective Date.

6.2 [REDACTED]

Article 7
Miscellaneous

7.1 [REDACTED]

7.2 [REDACTED]

[REDACTED]

7.3

[REDACTED]

7.4

[REDACTED]

7.5

[REDACTED]

[REDACTED]

7.6

[REDACTED]

7.7


[REDACTED]


7.8 This Agreement and all attachments, including exhibits and appendices, which are referenced herein, constitute the entire agreement among the Parties with respect to the matters set forth herein, and supersedes all prior agreements and understandings, both written and oral, among the Parties with respect thereto.

IN WITNESS WHEREOF the Parties have caused this Agreement to be executed by their duly authorized representatives as of the dates sets forth below;

Bayer Pharmaceuticals Corporation

Bayer HealthCare LLC

By: 

By: 

Name: R. Franzen

Name: PAUL G. DENNEY

Title: President & CEO

Title: SR VP & CA, BAYER HEALTHCARE LLC

Date: Aug. 8, 2007

Date: Aug. 13, 2007


Annex 1
Patents

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5216						
5278			US? PCT			
5007	WOOD JILL	RAF KINASE INHIBITORS	US	09/083,399	05/22/1998	6,187,799 B1
5007 ORIG.	WOOD JILL	RAF KINASE INHIBITORS	PCT/EPO	98 923 601.3	05/21/1998	
5007D1	WOOD JILL E.	RAF KINASE INHIBITORS	US	09/755,060	01/08/2001	
5007D2	WOOD JILL E.	RAF KINASE INHIBITORS	US	11/149,332	06/10/2005	
5008P1	RANGES GERALD	INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS	PCT/EPO	98923600.5	11/26/1999	1019040

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5008P1	RANGES GERALD	INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS	US	09/083,396	05/22/1998	6,344,476

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5008PID1	RANGES GERALD	INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS	US	109/947,761	09/07/2001	



Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5032P1	MILLER SCOTT	INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS	PCT/EPO	98963809.3	12/22/1998	1049664
5032P1	MILLER SCOTT	INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS	PCT/EPO D1	03 026 051.7	12/22/1998	

[illegible]

[illegible]

[illegible]

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5033P1	DUMAS JACQUES	INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS	PCT/EPO	98965981.8	12/22/1998	1 047 418

[illegible]


[illegible]

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5033P1C1	DUMAS JACQUES	INHIBITION OF RAK KINASE USING SUBSTITUTED HETEROCYCLIC UREAS	US	09/640,780	08/18/2000	
5033P1C2	DUMAS JACQUES	INHIBITION OF RAK KINASE USING SUBSTITUTED HETEROCYCLIC UREAS	US	11/768,112	06/25/2007	

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5034P1	DUMAS JACQUES	INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS	PCT/EPO	98963810.1	12/22/1998	1 056 725



[illegible]

[illegible]

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
[REDACTED]						

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5034P1C1	DUMAS JACQUES	INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS	US	09/472,232	12/27/1999	
5034P1C2	DUMAS JACQUES	INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS	US	11/768,533	06/26/2007	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5035P1	MILLER SCOTT	INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS	PCT/EPO	98964221.0	12/22/1998	1042305
5035P1	MILLER SCOTT	INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS	PCT/EPO DI	05012144.1	09/27/2005	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
[REDACTED]						

[illegible]

[illegible]

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5035PIC3	MILLER SCOTT	INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS	US	10/060,396	02/01/2002	
5036P1	DUMAS JACQUES	INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS	PCT/EPO	98964709.4	12/22/1998	1041982

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5036P1C1	DUMAS JACQUES	INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS	US	09/458,014	12/10/1999	
5036P1C2	DUMAS JACQUES	INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS	US	09/458,014	12/10/1999	
5037P1	DUMAS JACQUES	INHIBITION OF P38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS	PCT/EPO	98964708.6	12/22/1998	1043995

[illegible]

[illegible]

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5037P1	DUMAS JACQUES	INHIBITION OF P38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS	US	09/776,935	12/22/1998	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5049P2	RIEDL, BERND	OMEGA-CARBOXYPYRIDYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS	PCT/EPO	00905597.1	01/13/2000	


Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5049P2C2	RIEDL BERND	OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS	US	10/086,417	03/04/2002	
5049P3	RIEDL BERND	HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS P38 KINASE INHIBITORS	US	09/778,039	02/07/2001	

[illegible]

[illegible]

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5050P2	RIEDL BERND	OMEGA-CARBOXYPPYRIDYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS	PCT/EPO	00903239.2	01/12/2000	1140840
5050P2	RIEDL BERND	OMEGA-CARBOXYPPYRIDYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS	PCT/EPO DI	05028442.1	01/12/2000	



[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
[REDACTED]						

[illegible]

[illegible]

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5050F2	RIEDL BERND	OMEGA-CARBOXYPYRIDYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS	PCT/US	09/889,227	07/06/2001	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5050P2C1	RIEDL BERND	OMEGA-CARBOXYPYRIDYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS	US	09/948,915	09/10/2001	
5050P2D1			PCT/EP			

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5050P3		OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS	PCT			
5050P3	SCOTT WILLIAM J.	INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS	US	09/458,548	01/12/2001	
5050P4	DUMAS JACQUES	INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS	PCT/EPO	2704353.8	02/07/2002	
5050P4	DUMAS JACQUES	METHOD AND/OR PROCESS FOR PREPARING OMEGA- CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS	US	09/777,920	02/07/2001	
5050P5	RIEDL BERND		US	10/071,248	02/11/2002	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5068	RIEDL BERND	OMEGA CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS	US	09/993,647	11/27/2001	
5072	RIEDL BERND	OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS	US	10/042,226	01/11/2002	
5073	RIEDL BERND	OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS		10/042,203	01/11/2002	7,235,576
5073	RIEDL BERND	OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS	US	11/768,104	6/25/2007	
5074	SCOTT WILLIAM J.	INHIBITION OF RAF KINASE QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS	PCT/EPO	02725710.4	04/18/2002	1379505

[illegible]

[illegible]

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5074	SCOTT WILLIAM J.	INHIBITION OF RAF KINASE QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS	US	10/125,369	04/19/2002	
5074C1	SCOTT WILLIAM J.	INHIBITION OF RAF KINASE QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS	US	11/158,048	06/22/2005	
5075	DUMAS JACQUES	HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS P38 KINASE INHIBITORS	PCT/EPO	02725709.6	04/17/2002	
5075	DUMAS JACQUES	HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS P38 KINASE INHIBITORS	US	09/838,286	04/20/2001	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5110	DUMAS JACQUES	ARYL UREAS AS KINASE INHIBITORS	PCT/EPO	03707848.2	02/11/2003	
5110	DUMAS JACQUES	ARYL UREAS AS KINASE INHIBITORS	US	10/361,859	02/11/2003	
5110C1	DUMAS JACQUES	ARYL UREAS AS KINASE INHIBITORS	US			
5110D1	DUMAS JACQUES	ARYL UREAS AS KINASE INHIBITORS	PCT/EP	5007027.5	37663	
5111	SCOTT WILLIAM J.	PYRIDINE QUINOLINE AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS	US	10/361,850	02/11/2003	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5112	CARTER CHRISTOPHER	ARYL UREA COMPOUNDS IN COMBINATION WITH OTHER CYTOSTATIC OR CYTOTOXIC AGENTS FOR TREATING HUMAN CANCERS	PCT/EPO	02786842.1	12/03/2002	1450799
5112	CARTER CHRISTOPHER	ARYL UREA COMPOUNDS IN COMBINATION WITH OTHER CYTOSTATIC OR CYTOTOXIC AGENTS FOR TREATING HUMAN CANCERS	PCT/EPO DI	06023696.5	11/14/2006	

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5112	CARTER CHRISTOPHER	ARYL UREA COMPOUNDS IN COMBINATION WITH OTHER CYTOSTATIC OR CYTOTOXIC AGENTS FOR TREATING HUMAN CANCERS	US	10/308,187	12/03/2002	
5112C1	CARTER CHRISTOPHER	ARYL UREA COMPOUNDS IN COMBINATION WITH OTHER CYTOSTATIC OR CYTOTOXIC AGENTS FOR TREATING HUMAN CANCERS	US	11/480,360	07/05/2006	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5138	EVELEIGH DEEPA	METHODS FOR PREDICTION AND PROGNOSIS OF CANCER AND MONITORING CANCER THERAPY	PCT/EPO	03781302.9	09/30/2003	
5138	EVELEIGH DEEPA	METHODS FOR PREDICTION AND PROGNOSIS OF CANCER AND MONITORING CANCER THERAPY	US	10/675,406	09/30/2003	
5153	DUMAS JACQUES	2-OXO-1,3,5- PERHYDROTRIAZAPINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER- PROLIFERATIVE, ANGIOGENESIS, AND INFLAMMATORY DISORDERS	PCT/EPO	04716136.9	03/01/2004	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5153	DUMAS JACQUES	2-OXO-1,3,5-PERHYDROTRIAZAPINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE, ANGIOGENESIS, AND INFLAMMATORY DISORDERS	PCT/US			
5153	DUMAS JACQUES	2-OXO-1,3,5-PERHYDROTRIAZAPINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE, ANGIOGENESIS, AND INFLAMMATORY DISORDERS	US	10/788,405	03/01/2004	
5154	DUMAS JACQUES	SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS	PCT/EPO			
5154	DUMAS JACQUES	SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS	PCT/US			

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5154	DUMAS JACQUES	SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS	US	10/789,446	03/01/2004	
5155	DUMAS JACQUES	NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS	PCT/EPO	04716166.6	03/01/2004	
5155	DUMAS JACQUES	NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS	PCT/US			
5155	DUMAS JACQUES	NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS	US	10/788,426	03/01/2004	

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
[REDACTED]						

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Docket	First Inventor	Title	Country	App. No	Filing Date	Patent No.
5160P1	BOYER STEPHAN	FLORO-SUBSTITUTED OMEGACARBOXYLARLY DIPHENYL UREAS FOR THE TREATMENT OF CANCER AND OHTER PROLIFERATIVE DISORDERS	US	10/895,985	07/22/2004	
5171	WILHELM SCOTT	DIARYL UREAS WITH RAF KINASE INHIBITING ACTIVITY	PCT/EPO	4752642.1	05/19/2004	
5171	WILHELM SCOTT	DIARYL UREAS WITH RAF KINASE INHIBITING ACTIVITY	US	10/571,100	05/19/2004	
5171C1	WILHELM SCOTT	DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR	PCT			
5171C1	WILHELM SCOTT	DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR	PCT/EP	4776037.6	38705	39267

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5171 P1	WILHELM SCOTT	DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR	US	10/848,567	5/19/2004	
5181	TAYLOR IAN	IMMUNOHISTOCHEMICAL METHODS	PCT/EPO	04818346.1	11/04/2004	
5181	TAYLOR IAN	IMMUNOHISTOCHEMICAL METHODS	US	10/576,733	04/21/2006	
5184	KASPER JAMES	METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY	PCT/EPO	04814106.3	12/10/2004	
5184	KASPER JAMES	METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY	US	10/581,125	05/30/2006	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5187	SCOTT WILLIAM J.	CYANO PYRIDINES	PCT/EPO	04716144.3	03/01/2004	
5187	SCOTT WILLIAM J.	CYANO PYRIDINES	PCT/US			
5187	SCOTT WILLIAM J.	CYANO PYRIDINES	US	10/788,029	02/27/2004	

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5222	DUMAS JACQUES	NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPER- PROLIFERATIVE DISORDERS	PCT/EPO	05792486.2	08/29/2005	

[illegible]

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5222	DUMAS JACQUES	NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPER- PROLIFERATIVE DISORDERS	US	11/212,109	08/26/2005	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5223	SCHUCKLER FRITZ	NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER	PCT			
5223	SCHUCKLER FRITZ	NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER	PCT/EPO			
5223	SCHUCKLER FRITZ	NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER	US	11/212,907	08/29/2005	
5230	LEE WENDY	SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER	PCT/EPO			
5230	LEE WENDY	SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER	US	11/579,093	10/30/2006	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
5257	WILHELM SCOTT	TREATMENT OF CANCER WITH SORAFENIB	PCT		10/31/2006	
5258	WILHELM SCOTT	DIARYL UREAS AND INTERFERON COMBINATIONS	PCT		10/31/2006	
5259	WILHELM SCOTT	METHODS FOR PROGNOSIS AND MONITORING CANCER THERAPY	US	11/589,295	10/30/2006	
5261	WILHELM SCOTT	TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS	PCT		11/14/2006	
5262	WILHELM SCOTT	TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS	PCT		11/14/2006	
5269	ELTING JAMES	METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY	US	11/598,824	11/14/2006	
5269			PCT	PCT/US06/44117	39035	
5271	KELLEY SUSAN	DRUG COMBINATIONS WITH SUBSTITUTED DIARYL UREAS FOR THE TREATMENT OF CANCER	US	11/754,082	05/25/2007	
5271			PCT	PCT/US07/12477	5/25/2007	
5285 PROVISIO NAL	WILHELM SCOTT	TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS	US	60/885,728	01/19/2007	
5286 PROVISIO NAL	WILHELM SCOTT	TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS	US	60/885,731	01/19/2007	

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
BHC 041061	LOGERS MICHAEL	PROCESS FOR THE PREPARATION OF 4-[[[4- CHLORO-3- (TRIFLUOROMETHYL)PHENYL LJAMINO}PHENOXY}-N- METHYLPIRIDINE-2- CARBOXAMIDE	US	11/664,332	03/29/2007	
BHC 041314	GRUNENBERG ALFONS	THERMODYNAMICALLY STABLE FORM OF BAY 43- 9006 TOSYLATE			03/29/2007	
BHC 051005	SHUCKLER FRITZ	PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREA FOR THE TREATMENT OF CANCER	US	11/885,930	09/07/2007	
BHC 051056	SCHEURING URBAN	COMBINATION THERAPY COMPRISING DIARYL UREAS FOR TREATING DISEASES	US		11/21/2007	
BHC 051057	SCHEURING URBAN	COMBINATION THERAPY COMPRISING A DIARYL UREA COMPOUND AND A PI3, AKT KINASE OR MTOR INHIBITORS (RAPAMYCINS) FOR CANCER TREATMENT	US		11/21/2007	
BHC 051125						
BHC 051126						
BHC 051130						
BHC 051131						
BHC 051138						

Docket	First Inventor	Title	Country	App No	Filing Date	Patent No.
BHC 051139						
BHC 051154						
BHC 051155						
BHC 061143						
BHC 061179						
BHC 061180						